ArticleChildhood kidney diseases2026
Efficacy and safety of nafamostat mesilate in pediatric continuous renal replacement therapy: a 5-year retrospective study in South Korea.
Article in Childhood kidney diseases, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Purpose: This study aimed to evaluate the efficacy and safety of a nafamostat mesilate (NM) protocol in pediatric patients undergoing continuous renal replacement therapy (CRRT). Methods: A retrospective review was performed in 107 patients who underwent at least 24 hours of CRRT between January 2018 and December 2022 at Samsung Medical Center. According to the anticoagulation strategy used during CRRT, patients were categorized into three groups: no anticoagulation (Group 1), NM (Group 2), and heparin (Group 3). Results: A total of 107 patients (mean age 7.8±5.5 years) were included. The mean duration of CRRT was 11.7 days, and the overall survival rate was 61.7%. NM and heparin were administered to 38 and 27 patients, respectively, whereas 42 patients received no anticoagulant therapy. Mean filter life did not differ significantly among the groups (no anticoagulation 32.1 hours vs. NM 26.7 hours vs. heparin 33.9 hours; Conclusions: NM appears to be a safe anticoagulation option in pediatric CRRT patients at high bleeding risk. While overall filter life was comparable across groups, NM significantly prolonged hemofilter lifespan in patients switched from no anticoagulation, supporting its potential role as a rescue strategy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.